Daniel S. Meyers

Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.

Ludger Scheja, Liza Makowski, K. Teoman Uysal et al. · Diabetes · 1999 · 219 citations

Life Sciences, Biochemistry, Endocrinology +17

Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering

Tracy Mitchell, Doree Sitkoff, Fred Lo et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 132 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice

Cynthia Arbeeny, Daniel S. Meyers, D.E. Hillyer et al. · American Journal of Physiology-Endocrinology and Metabolism · 1995 · 52 citations

Medicine, Endocrinology, Pharmacology +17

Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)

Jun Li, Lawrence J. Kennedy, Yan Shi et al. · Journal of Medicinal Chemistry · 2010 · 41 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Beryl B. Cummings, Mark Joing, Page Bouchard et al. · The Lancet · 2025 · 36 citations

Pharmacy, Pharmacology, Pharmacotherapy +15